Modulating Cell Cycle Progression in T Cells

All cell cycle inhibitors were titrated on CFSE labeled CD8 T cells to identify a dose that inhibited proliferation by approximately 50%. Mouse and human CD8 T cells showed similar responses to each drug; therefore, the same concentrations were used for both species. Palbociclib (PD 0332991, Sigma product #PZ0383) was used at 500nM. Abemaciclib (LY2835219, obtained from Eli Lilly Pharmaceuticals) was used at 100 nM. Ribociclib (LEE011, Selleckchem product #S7440) was used at 200 nM. CDK1/2i (RO-3306, Selleckchem product #S7747) was used at 4.5 μM. Aurora kinase inhibitor (MLN-8054, Selleckchem product #S1100) was used at 1 μM. Polo-like kinase inhibitor (GSK-461364, Selleckchem product #S2193) was used at 0.15 μM. CDK7i (YKL-5124) was developed by Nathanael Gray’s lab as reported (53 (link)) and used at 100 nM. CDK4/6 degrader (BJS 2–162) was developed by Nathanael Gray’s lab as reported (32 (link)) and used at 2 μM.